Industrias Unidas, S.A. de C.V. Consolidated Results of Operations for Q1 2025
MEXICO CITY, June 04, 2025--(BUSINESS WIRE)--Industrias Unidas, S.A. de C.V. ("IUSA" or the "Company") has announced its unaudited results for the three months ended March 31 of 2025. Figures are unaudited and have been prepared in accordance with Mexican Financial Reporting Standards ("MFRS"), which are different in certain respects from Generally Accepted Accounting Principles in the United States ("U.S. GAAP"). The results from any interim period are not necessarily indicative of the results that may be expected for a full fiscal year. Unless stated otherwise, reference herein to "Pesos", "pesos", or "Ps." are to pesos, the legal currency of Mexico and references to "U.S. dollars", "dollars", "U.S. $" or "$" are to United States dollars, the legal currency of the United States of America. Except as otherwise indicated, all peso amounts are presented herein in pesos with purchasing power as of March 31, 2025, and in pesos with their historical value for other dates cited. The dollar translations provided in this document are calculated solely for the convenience of the reader using an exchange rate of Ps. 20.46 per U.S. dollar, the exchange rate published by Banco de Mexico, the country's central bank, on March 31, 2025.
Three months ended March 31, 2025, compared to three months ended March 31, 2024.
The following table summarizes our results of operations for the three months ending March 31, 2025, and 2024:
(Figures in Millions of Pesos)
For the year ended March31,
2024
2025
Revenues
6,236.3
8,876.0
Cost of Sales
4,803.3
6,922.3
Gross Profit
1,433.0
1,953.7
Selling and Administrative Expenses
630.8
805.4
Operating Income (Loss)
802.2
1,148.3
Other Expenses - Net
51.2
21.8
Comprehensive Financing Result
63.8
34.9
Taxes and Statutory Employee Profit Sharing
180.9
290.4
Equity in Income (Loss) of Associated Companies
(16.0)
(2.8)
Consolidated Net Income (Loss)
720.3
911.8
D&A
71.5
82.2
EBITDA 1/
873.7
1,230.5
1/ EBITDA for any period is defined as consolidated net income (loss) excluding i) depreciation and amortization, ii) total net comprehensive financing result (which is comprised of net interest expense, exchange gain or loss, monetary position gain or loss and other Financing costs), iii) other expenses net, iv) income tax and statutory employee profit sharing and v) equity in income (loss) of associated companies. EBITDA should not be considered as an alternate measure of net income or operating income, as determined on a consolidated basis using amounts derived from statements of operations prepared in accordance with MFRS, or as an indicator of operating performance or to cash flows from operating activity as a measure of liquidity. EBITDA is not a recognized term under MFRS or U.S. GAAP and does not purport to be an alternative to net income as a measure of operating performance or to cash flows from operating activity as a measure of liquidity.
Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.6 million), compared to a net income of Ps.720.3 million in the same period of 2024. This represented a 26.6% increase, quarter over quarter (Q/Q). This change is primarily due to an increase in sales and hence Gross Profit.
Revenues
Our net revenues for the three months of 2025 increased 42.3% to Ps.8,876.0 million (U.S.$433.82 million) from Ps.6,236.3 million in the same period of 2024. This increase was driven in part by higher copper prices, combined with an increase in volume of sales.
Our costs and revenues follow copper prices very closely since the market practice is to pass on to the buyer changes in raw material prices.
Our sales are primarily for customers engaged in commercial, industrial and residential construction, and their related maintenance and renovation activities. We also sell to customers engaged in electrical power generation, transmission and distribution and to the sectors of gas, water and air conduction in Heating, Ventilation, Air conditioning and Refrigeration (HVACR).
Our revenues consist mainly of sales of copper-based products (tubing, wire, cable and alloys) and electrical products.
By country of production, approximately 61.3% of our revenues in the three months ended March 31, 2025, came from products manufactured in Mexico and the remaining 38.7% from products manufactured in the U.S.
In terms of sales by region during the three months ended March 31, 2025, we derived approximately 44.0% of our revenues from sales to customers in the United States, 51.7% from customers in Mexico and 4.3% from the rest of the world ("ROW").
Cost of sales
Our cost of sales in the three months ended March 31, 2025, increased by 44.1% to Ps.6,922.3 million (U.S.$338.3 million) from Ps.4,803.3 million in the same period of 2024. As a percentage of revenues, the cost of sales was 78.0% and 77.0% respectively.
We reduce our cost base through several initiatives, including plant scheduling, raw material handling, and overall manufacturing overhead costs. According to our accounting policies, we make an inventory valuation at an average purchase price. In the case of copper cathodes, an aftermath adjustment is required due to the quotation period agreed with the suppliers (M+1). This initiative allows us to hedge purchases for 30 days at no additional cost. The adjustment is recorded to the cost of sales in the month in which it occurs.
Gross Profit
Our gross profit in the three months ended March 31, 2025, increased 36.3% to Ps.1,953.7 million (U.S.$95.5 million) from Ps.1,433.0 million in the same period of 2024. As a percentage of sales, gross profit in 2025 was 22.0% vs 23.0% in 2024.
Selling and Administrative Expenses
Our sales and administrative expenses in the three months ended March 31, 2025, increased 27.7% to Ps.805.4 million from Ps.630.8 in the same period of 2024.
Operating Income
Our operating income in the three months ended March 31, 2025, increased 43.1% to Ps. 1,148.3 million (U.S.$56.12 million) from an operating income of Ps. 802.2 in the same period of 2024.
EBITDA
In the three months ended March 31, 2025, our EBITDA increased 40.8% to Ps.1,230.5 million (or U.S.$60.1million), from Ps.873.7 million in the same period of 2024. The corresponding depreciation and amortization figures are Ps.422.3 million for January to March 2025 and Ps.337.7 million for the same period of 2024.
Comprehensive Financing Result
The following table shows our comprehensive financing results for the three months ending March 31, 2025, and 2024:
(Figures in Millions of Pesos)
For the year ended March 31,
2024
2025
Interest Expense
(69.4)
(78.5)
Interest Income
51.3
30.6
Exchange Gain (Loss) - Net
88.7
88.9
Other Financing Costs
(6.8)
(6.1)
Comprehensive Financing Result
63.8
34.9
Our comprehensive financing result in the three months ending March 31, 2025, was an expense of Ps.34.9 million, compared to an expense of Ps.63.8 million in the same period of 2024.
Taxes and Statutory Employee Profit Sharing
The provision for current and deferred income taxes and statutory employee profit sharing in the three months ended March 31, 2025, was an expense of Ps.290.4 million compared to an expense of Ps.180.9 million in the same period of 2024.
Consolidated Net Income
Our consolidated net income for the three months ended March 31, 2025, was Ps.911.8 million (U.S.$44.5 million), compared to a net income of Ps.720.3 million in the same period of 2024.
Liquidity and Capital Resources
Liquidity
As of March 31, 2025, we had cash and cash equivalents for Ps.6,436.8 million (U.S.$314.6 million). Our policy is to invest available cash in short-term instruments issued by Mexican and U.S. banks as well as in securities issued by the governments of Mexico and the U.S.
Our cash flow from operations and operating margins are significantly influenced by world market prices for raw copper, as quoted by COMEX and the London Metal Exchange ("LME"). Copper prices are subject to significant market fluctuations; average copper prices increased 18.4% in the three months ending March 31, 2025, to $4.57 US dollars per pound from $3.86 US dollar per pound in the same period of 2024.
We obtain short-term financing from various sources, including Mexican and international banks. Short-term financing consists in part of lines of credit denominated in pesos and dollars. As of March 31, 2025, our outstanding short-term debt, including the current portion of long-term debt totaled Ps.422.2 million (U.S.$20.6 million), all of which was dollar denominated.
On the same date, our outstanding consolidated long-term debt, excluding current portion thereof, totaled Ps.4,129.0 million (U.S.$201.8 million), all of which was dollar denominated.
Accounts receivable from third parties as of March 31, 2025, were Ps.6,205.1 million (U.S.$303.3 million). Days outstanding in the domestic market were 31 days as of March 31, 2025.
Debt Obligations
The following table summarizes our debt as of March 31, 2025:
Consolidated debt
March 31, 2025
(In Millions of Pesos)
U.S. subsidiaries debt
35.9
Mexican debt
4,515.4
Total
4,551.3
This total includes the restructured debt of the Company.
Capital Expenditures
For the three months ended March 31, 2025, we invested Ps.79.1 million (U.S. $3.9 million) in capital expenditure projects, mainly related to expansion of production and maintenance.
In the three months ending March 31, 2025, our capital expenditures were allocated by segments as follows: 1.0% to copper tubing, 35.0% to wire and cable, 45.0% to valves and controls, 8.0% to electrical products and the remaining and 11.0% to other divisions. By geographic region 69.0% of total capital expenditures were invested in our Mexican facilities and the remaining 31.0% in the U.S.
You should read this document in conjunction with the unaudited consolidated financial statements as of March 31, 2025, including the notes to those statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604742278/en/
Contacts
Francisco Rodriguez, frodriguez@iusa.com.mx, tel. 5255 5216 4028
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 hours ago
- Business Wire
EMEREN GROUP INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Emeren Group Ltd.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Emeren Group Ltd. (NYSE: SOL) to Shurya Vitra Ltd. Under the terms of the proposed transaction, shareholders of Emeren Group will receive $0.20 in cash per ordinary share or $2.00 in cash per American Depositary Share. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
17 hours ago
- Business Wire
COUCHBASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Couchbase, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Couchbase, Inc. (NasdaqGS: BASE) to Haveli Investments. Under the terms of the proposed transaction, shareholders of Couchbase will receive $24.50 in cash for each share of Couchbase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit
Business Wire
18 hours ago
- Business Wire
OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions
MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit
